Longevity advocacy succeeds by tailoring its message. To fiscal conservatives, it's a way to reduce Medicare spending. To progressive Democrats, it's about using mass-produced drugs to achieve health equity and close the gap between the wealthy and the poor.

Contrary to the ageist view that an older population drains resources, healthy older individuals represent a massive, untapped asset. Their accumulated wisdom, experience, and wealth are a form of "gold" that society must learn to mine by creating opportunities rather than pushing them aside.

Beyond tackling fatal diseases to increase lifespan, a new wave of biotech innovation focuses on "health span"—the period of life lived in high quality. This includes developing treatments for conditions often dismissed as aging, such as frailty, vision loss, and hearing decline, aiming to improve wellbeing in later decades.

Anti-aging treatments will pay for themselves by eliminating the enormous medical costs of late-life health problems. This creates a powerful economic imperative for governments to ensure universal access, countering the common fear that such therapies will only be available to the wealthy.

A major transformation has occurred in longevity science, particularly in the last eight years. The conversation has moved away from claims of radical life extension towards the more valuable goal of increasing "healthspan"—the period of healthy, functional life. This represents a significant and recent shift in scientific consensus.

The economic value of extending healthy life is astronomical. One research team estimated a single year of added healthspan is worth $38 trillion to the US economy, a figure experts believe is still an underestimate. This reframes geroscience investment as a massive economic opportunity, not a cost.

The economic benefit of longevity, termed the "longevity dividend," is massive. Each additional year of healthy, productive life adds trillions of dollars to the GDP. This economic argument justifies significant government and private investment into aging research, as the societal ROI is immense.

Current healthcare spending, or "Aging 1.0," focuses on managing age-related decline via retirement homes and late-stage care. The new paradigm, "Aging 2.0," uses biotechnology to prevent the need for this maintenance in the first place, representing a fundamental strategic shift.

The common aversion to living to 120 stems from assuming extra years will be spent in poor health. The goal of longevity science is to extend *healthspan*—the period of healthy, mobile life—which reframes the debate from merely adding years to adding high-quality life.